AU Patent

AU2020344561A1 — Pharmaceutical formulations of indoleamine 2, 3-dioxygenase inhibitors

Assigned to Bristol Myers Squibb Co · Expires 2022-04-21 · 4y expired

What this patent protects

The present application is directed to a pharmaceutical composition comprising (

USPTO Abstract

The present application is directed to a pharmaceutical composition comprising (

Drugs covered by this patent

rucaparib-camsylate (RUCAPARIB CAMSYLATE)

Patent Metadata

Patent number: AU2020344561A1
Jurisdiction: AU
Classification: —
Expires: 2022-04-21
Drug substance claim: No
Drug product claim: No
Assignee: Bristol Myers Squibb Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.